Suchitrita S. Rathmann

735 total citations
22 papers, 562 citations indexed

About

Suchitrita S. Rathmann is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Suchitrita S. Rathmann has authored 22 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 9 papers in Immunology and 7 papers in Hematology. Recurrent topics in Suchitrita S. Rathmann's work include Spondyloarthritis Studies and Treatments (14 papers), Rheumatoid Arthritis Research and Therapies (11 papers) and Psoriasis: Treatment and Pathogenesis (9 papers). Suchitrita S. Rathmann is often cited by papers focused on Spondyloarthritis Studies and Treatments (14 papers), Rheumatoid Arthritis Research and Therapies (11 papers) and Psoriasis: Treatment and Pathogenesis (9 papers). Suchitrita S. Rathmann collaborates with scholars based in United States, Germany and Netherlands. Suchitrita S. Rathmann's co-authors include H. Küpper, Roy Fleischmann, Udayasankar Arulmani, Gerd‐Rüdiger Burmester, S. Florentinus, Sandra Goss, Alan Kivitz, Désirée van der Heijde, Catherine L Shuler and Dafna D. Gladman and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

Suchitrita S. Rathmann

21 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suchitrita S. Rathmann United States	10	386	264	199	60	59	22	562
Т. В. Коротаева Russia	14	695 1.8×	632 2.4×	302 1.5×	23 0.4×	58 1.0×	163	847
Eleni Kampylafka Germany	11	411 1.1×	271 1.0×	163 0.8×	71 1.2×	41 0.7×	23	539
Dèlia Reina Spain	11	238 0.6×	84 0.3×	75 0.4×	54 0.9×	10 0.2×	53	427
Joan Calvet Spain	12	295 0.8×	117 0.4×	49 0.2×	22 0.4×	38 0.6×	51	487
Vidya Ranganathan Canada	7	364 0.9×	380 1.4×	168 0.8×	19 0.3×	29 0.5×	8	655
Diletta Bonciani Italy	11	204 0.5×	80 0.3×	55 0.3×	104 1.7×	166 2.8×	22	450
Vanesa Hernández-Hernández Spain	10	176 0.5×	85 0.3×	83 0.4×	50 0.8×	14 0.2×	24	323
H. Bastian Germany	9	390 1.0×	80 0.3×	138 0.7×	42 0.7×	8 0.1×	21	478
M B Bertolo Brazil	6	219 0.6×	57 0.2×	110 0.6×	50 0.8×	13 0.2×	6	293
Timothy Shaver United States	8	271 0.7×	68 0.3×	86 0.4×	75 1.3×	31 0.5×	13	360

Countries citing papers authored by Suchitrita S. Rathmann

Since Specialization

Citations

This map shows the geographic impact of Suchitrita S. Rathmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suchitrita S. Rathmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suchitrita S. Rathmann more than expected).

Fields of papers citing papers by Suchitrita S. Rathmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suchitrita S. Rathmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suchitrita S. Rathmann. The network helps show where Suchitrita S. Rathmann may publish in the future.

Co-authorship network of co-authors of Suchitrita S. Rathmann

This figure shows the co-authorship network connecting the top 25 collaborators of Suchitrita S. Rathmann. A scholar is included among the top collaborators of Suchitrita S. Rathmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suchitrita S. Rathmann. Suchitrita S. Rathmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adang, Laura, C. J. Malanga, Barbara K. Burton, et al.. (2024). A phase 2 study assessing TAK-611150 mg intrathecal weekly in patients with late-infantile metachromatic leukodystrophy (SHP611–201; EMBOLDEN) compared to matched historical control data from children with late-infantile MLD (GLIA-MLD). Molecular Genetics and Metabolism. 141(2). 107744–107744.

Smith, Timothy R., John H. Krege, Suchitrita S. Rathmann, et al.. (2020). Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies. Neurology and Therapy. 9(2). 459–471. 9 indexed citations

Tepper, Stewart J., Raghavendra Vasudeva, John H. Krege, et al.. (2020). Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks. Headache The Journal of Head and Face Pain. 60(8). 1601–1615. 20 indexed citations

Chandran, Vinod, Désirée van der Heijde, Roy Fleischmann, et al.. (2020). Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Lara D. Veeken. 59(10). 2774–2784. 38 indexed citations

Gladman, Dafna D., Ana‐Maria Orbai, James Cheng‐Chung Wei, et al.. (2019). Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Research & Therapy. 21(1). 38–38. 30 indexed citations

Gladman, Dafna D., Ana‐Maria Orbai, Gaia Gallo, et al.. (2018). SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials. Annals of the Rheumatic Diseases. 77. 1025–1025. 1 indexed citations

Nash, Peter, Frank Behrens, Ana‐Maria Orbai, et al.. (2018). Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open. 4(2). e000692–e000692. 18 indexed citations

Heijde, Désirée van der, Dafna D. Gladman, Mitsumasa Kishimoto, et al.. (2017). Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). The Journal of Rheumatology. 45(3). 367–377. 96 indexed citations

Heijde, Désirée van der, Masato Okada, Chin Lee, et al.. (2017). Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks. SKIN The Journal of Cutaneous Medicine. 1. s28–s28. 2 indexed citations

10.

Heijde, Désirée van der, et al.. (2017). OP0221 Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks. Annals of the Rheumatic Diseases. 76. 144–145. 1 indexed citations

11.

Mallinckrodt, Craig, Geert Molenberghs, & Suchitrita S. Rathmann. (2016). Choosing estimands in clinical trials with missing data. Pharmaceutical Statistics. 16(1). 29–36. 31 indexed citations

12.

Burmester, Gerd‐Rüdiger, Alan Kivitz, H. Küpper, et al.. (2014). Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the Rheumatic Diseases. 74(6). 1037–1044. 183 indexed citations

13.

Heijde, Désirée van der, Maxime Bréban, D Halter, et al.. (2014). Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Lara D. Veeken. 54(7). 1210–1219. 42 indexed citations

14.

Sieper, Joachim, Dominique Baeten, Filip Van den Bosch, et al.. (2014). 215. Sustained Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Treatment. Lara D. Veeken. 53(suppl_1). i140–i140. 1 indexed citations

15.

Heijde, Désirée van der, Walter P. Maksymowych, Joachim Sieper, et al.. (2014). 229. Relationship Between MRI AND Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis After Two Years of Adalimumab Therapy. Lara D. Veeken. 53(suppl_1). i145–i145. 1 indexed citations

16.

Sieper, J., Désirée van der Heijde, Maxime Dougados, et al.. (2013). SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH POSITIVE MRI OF THE SACROILIAC JOINTS OR SPINE OR ELEVATED C-REACTIVE PROTEIN AT BASELINE. Lara D. Veeken. 52. 52–53. 1 indexed citations

17.

Sieper, Joachim, Dominique Baeten, Filip Van den Bosch, et al.. (2013). OP0109 Sustained Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Treatment. Annals of the Rheumatic Diseases. 72. A88–A88. 1 indexed citations

18.

Sieper, Joachim, Walter P. Maksymowych, Matthew A. Brown, et al.. (2013). Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology. 66(3). 667–673. 61 indexed citations

19.

Burmester, Gerd R, Alan Kivitz, H. Küpper, et al.. (2013). OP0067 Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination with Adalimumab: Results from the Concerto Trial. Annals of the Rheumatic Diseases. 72. A72–A73. 3 indexed citations

20.

Berg, Aloys, et al.. (1999). The gastrointestinal system--an essential target organ of the athlete's health and physical performance.. PubMed. 5. 78–95. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact